KR20220148811A - 화합물 및 방사성 표지 화합물 - Google Patents

화합물 및 방사성 표지 화합물 Download PDF

Info

Publication number
KR20220148811A
KR20220148811A KR1020227028695A KR20227028695A KR20220148811A KR 20220148811 A KR20220148811 A KR 20220148811A KR 1020227028695 A KR1020227028695 A KR 1020227028695A KR 20227028695 A KR20227028695 A KR 20227028695A KR 20220148811 A KR20220148811 A KR 20220148811A
Authority
KR
South Korea
Prior art keywords
compound
formula
group
albumin
psma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227028695A
Other languages
English (en)
Korean (ko)
Inventor
요시후미 마야
마사히로 오노
심페이 이이쿠니
Original Assignee
니혼 메디피직스 가부시키가이샤
고쿠리츠 다이가쿠 호진 교토 다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니혼 메디피직스 가부시키가이샤, 고쿠리츠 다이가쿠 호진 교토 다이가쿠 filed Critical 니혼 메디피직스 가부시키가이샤
Publication of KR20220148811A publication Critical patent/KR20220148811A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0465—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227028695A 2020-03-04 2021-03-04 화합물 및 방사성 표지 화합물 Pending KR20220148811A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020037150 2020-03-04
JPJP-P-2020-037150 2020-03-04
PCT/JP2021/008333 WO2021177390A1 (ja) 2020-03-04 2021-03-04 化合物及び放射性標識化合物

Publications (1)

Publication Number Publication Date
KR20220148811A true KR20220148811A (ko) 2022-11-07

Family

ID=77612690

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227028695A Pending KR20220148811A (ko) 2020-03-04 2021-03-04 화합물 및 방사성 표지 화합물

Country Status (9)

Country Link
US (1) US20230112418A1 (https=)
EP (1) EP4116306A4 (https=)
JP (1) JPWO2021177390A1 (https=)
KR (1) KR20220148811A (https=)
CN (1) CN115210240A (https=)
AU (1) AU2021230210A1 (https=)
CA (1) CA3174082A1 (https=)
TW (1) TWI908773B (https=)
WO (1) WO2021177390A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116940557A (zh) * 2021-03-04 2023-10-24 日本医事物理股份有限公司 化合物及放射性标记化合物
AU2022228911A1 (en) * 2021-03-04 2023-09-21 Kyoto University Compound and radioactive labeling compound
WO2024249278A2 (en) * 2023-05-26 2024-12-05 Cornell University Macrocyclic chelators and methods of use for the separation of rare earth elements
WO2025189134A1 (en) * 2024-03-08 2025-09-12 ARTBIO, Inc. Methods for treating prostate cancer with radiopharmaceuticals
WO2025220711A1 (ja) * 2024-04-17 2025-10-23 日本メジフィジックス株式会社 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
WO2026014283A1 (ja) * 2024-07-09 2026-01-15 日本メジフィジックス株式会社 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物
CN119798110B (zh) * 2025-01-02 2025-09-26 吉林大学 一种4-（对碘苯基）丁基修饰的长循环衣康酸衍生物及制备方法和医用用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017196806A1 (en) 2016-05-09 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
WO2018098390A1 (en) 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
WO2019075583A1 (en) 2017-10-22 2019-04-25 British Columbia Cancer Agency Branch NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102605A1 (en) * 1991-05-23 1992-11-24 Evan C. Unger Liposoluble compounds for magnetic resonance imaging
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2760839C (en) 2009-05-01 2019-02-12 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
DE102014115154A1 (de) * 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
CN108699108B (zh) 2016-03-01 2022-04-08 国立大学法人千叶大学 放射性标记药物
US11167050B2 (en) 2017-09-26 2021-11-09 National University Corporation Chiba University Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound
EP3774803A1 (en) * 2018-03-30 2021-02-17 Centre national de la recherche scientifique Pyclen-based macrocyclic ligands, chelates thereof and uses thereof
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
MX2021008230A (es) 2019-01-07 2021-08-11 Astellas Pharma Inc Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5.
CN114364405B (zh) * 2019-04-26 2024-07-16 五一一制药股份有限公司 作为诊断剂和放射性核素治疗剂的前列腺特异性膜抗原(psma)抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017196806A1 (en) 2016-05-09 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
WO2018098390A1 (en) 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
WO2019075583A1 (en) 2017-10-22 2019-04-25 British Columbia Cancer Agency Branch NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Also Published As

Publication number Publication date
JPWO2021177390A1 (https=) 2021-09-10
EP4116306A4 (en) 2024-05-29
CA3174082A1 (en) 2021-09-10
AU2021230210A1 (en) 2022-09-22
CN115210240A (zh) 2022-10-18
US20230112418A1 (en) 2023-04-13
TW202146420A (zh) 2021-12-16
EP4116306A1 (en) 2023-01-11
TWI908773B (zh) 2025-12-21
WO2021177390A1 (ja) 2021-09-10

Similar Documents

Publication Publication Date Title
KR20220148811A (ko) 화합물 및 방사성 표지 화합물
AU2018308699B2 (en) Dual mode radiotracer and -therapeutics
CN108541302B (zh) 用于成像和治疗的尿素基前列腺特异性膜抗原(psma)抑制剂
EP4303213A1 (en) Compound and radioactive labeling compound
US9115094B2 (en) Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
KR20200009091A (ko) 신규 psma-결합제 및 이의 용도
US10842893B2 (en) Multifunctional chelators, complexes, and compositions thereof, and methods of using same
US20120219495A1 (en) Novel tetraaza macrocyclic compound, preparation method thereof and use thereof
Hueting et al. Bis (thiosemicarbazones) as bifunctional chelators for the room temperature 64-copper labeling of peptides
CN114502528A (zh) 成像和治疗组合物
KR20230162589A (ko) 이중 모드 방사성 트레이서 및 -치료제
Southcott et al. Trastuzumab-conjugated oxine-based ligand for [89Zr] Zr4+ immunoPET
HK40078050A (en) Compound and radioactive labeling compound
JP2025514068A (ja) セラノスティックフッ化ケイ素複素芳香族系およびその方法
KR101253100B1 (ko) 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
WO2013060793A1 (en) Bifunctional ligands for radiometals
CN116940557A (zh) 化合物及放射性标记化合物
HK40092961A (zh) 化合物及放射性标记化合物
WO2025220711A1 (ja) 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
Lodhi Synthesis and In Vivo Biological Evaluation of 99mTc (I) Tri-carbonyl Based Radiopharmaceuticals for SPECT Imaging
WO2026014283A1 (ja) 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物
KR20250049308A (ko) 방사성 의약품용 규소계 불화물 수용기
WO2025218677A1 (zh) 双重靶向成纤维细胞激活蛋白和整合素亚型的化合物及其制备和应用
US20140199243A1 (en) Bifunctional phosphonate chelating agents
JP2024501947A (ja) トレーサー化合物およびその調製方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000